Business Context and Reporting Period
This Form 8-K Current Report, dated September 24, 2020, covers Greenwich LifeSciences, Inc. (GLSI), a Delaware corporation. The filing announces the Company's Initial Public Offering (IPO) and the commencement of trading on The Nasdaq Capital Market under the symbol "GLSI" on September 25, 2020.
Key Financial Metrics and Capital Structure
- Offering Size: 1,260,870 shares of common stock sold at an initial public offering price of $5.75 per share.
- Over-Allotment Option: Underwriters hold an option to purchase an additional 189,130 shares at the same price.
- Net Proceeds: Approximately $6.5 million after deducting underwriting discounts, fees, and expenses.
- Representative's Warrants: Issuance of warrants to purchase 100,870 shares (8% of total shares issued) at an exercise price of $7.1875 per share (125% of the IPO price).
- Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Events
The primary material event is the entry into a Material Definitive Agreement (Underwriting Agreement) with Aegis Capital Corp. This marks the Company's transition to a publicly traded entity. The Offering is expected to close on or about September 29, 2020, subject to customary closing conditions.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Management anticipates using net proceeds primarily for clinical trials, manufacturing of product candidates, retention of contract research organizations, and working capital/general corporate purposes.
- Emerging Growth Company: The registrant has elected to be classified as an emerging growth company.
- Risks and Contingencies: The filing notes that the summary of the Underwriting Agreement is subject to customary representations and warranties. Specific risk factors are not detailed in this 8-K text but are referenced in the Registration Statement (Form S-1).
Investor Verification Checklist
- Verify the final closing date of the Offering (expected September 29, 2020) and whether the over-allotment option was exercised.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and indemnification terms.
- Examine the Registration Statement (Form S-1, File No. 333-238829) for detailed financial statements, risk factors, and the specific status of clinical trials.
- Confirm the actual net proceeds received after all transaction costs are finalized.